Incepta launches Pfizer’s anti-Covid pill | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 10, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 10, 2025
Incepta launches Pfizer’s anti-Covid pill

Covid-19 in Bangladesh

TBS Report
19 January, 2022, 04:00 pm
Last modified: 19 January, 2022, 06:56 pm

Related News

  • One dies from COVID-19 in 24 hrs
  • Covid-19: Two more deaths, 7 new cases reported in 24hrs
  • Covid-19: One more death, 10 new cases reported in 24hrs
  • Three die from Covid-19 in 24 hrs
  • Five Covid-19 deaths reported in 24 hours, 36 new cases detected

Incepta launches Pfizer’s anti-Covid pill

The drug is co-packaged with Nirmatrelvir and Ritonavir tablets

TBS Report
19 January, 2022, 04:00 pm
Last modified: 19 January, 2022, 06:56 pm
Incepta launches Pfizer’s anti-Covid pill

Incepta has announced the launching of Paxlovid, Pfizer's oral antiviral medication for the treatment of Covid-19.

Incepta Pharmaceuticals Limited will market the drug under the brand name Jupitavir, reads a press release. 

The Directorate General of Drug Administration (DGDA) granted emergency use authorisation for the drug to treat mild-to-moderate Covid-19 patients including adults and children aged 12 years and above.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Earlier on 22 December, the US Food and Drug Administration (US FDA) granted emergency use authorisation to the drug as the first approved oral therapy for Covid-19 treatment.

The antiviral pill showed almost 90% efficacy in preventing hospitalisations and deaths in high-risk patients, and recent lab data suggests that the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus.

The drug is co-packaged with Nirmatrelvir and Ritonavir tablets.

Nirmatrelvir inhibits a SARS-CoV-2 enzyme to stop the virus from replicating, and Ritonavir slows down Nirmatrelvir's breakdown to help it remain in the body for a longer period at higher concentrations.

The treatment is given as two tablets of Nirmatrelvir and one tablet of Ritonavir together twice a day for five days.

Jupitavir is available by prescription only and should be initiated as soon as possible after diagnosis of Covid-19 and within five days of symptom onset.

Earlier on 30 December, Beximco and Eskayef, two leading pharmaceutical companies in the country, had separately launched Paxlovid. Beximco Pharmaceuticals Limited marketed the drug under the brand name of Bexovid, while Eskayef marketed it as Paxovir.
 

Top News / Health

COVID-19 / Paxlovid / Covid oral drug / Incepta pharmaceuticals

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • Photo: TBS
    SSC 2025: Girls dominate boys by over 5%
  • BBC reported that the phone call took place on 18 July last year while Hasina was at Ganabhaban in Dhaka. Photo: TBS
    How BBC verified Hasina’s leaked audio ordering deadly crackdown during July Uprising

MOST VIEWED

  • Graphics: TBS
    BB raises startup fund limit, drops upper age barrier
  • Workers pack undergarments at the packing section of a garment factory in Ashulia, on the outskirts of Dhaka, Bangladesh, April 19, 2025. Photo: REUTERS/Fatima Tuj Johora
    After US tariffs, jobs hang by a thread in Bangladesh's garments sector
  • Global Islami Bank rectifies 2023 figures, reports Tk2,259cr loss instead of Tk128cr profit
    Global Islami Bank rectifies 2023 figures, reports Tk2,259cr loss instead of Tk128cr profit
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Audit reports of most banks contain cooked up data: BB governor
  • File photo of containers at Chattogram port/TBS
    US buyers push Bangladeshi exporters to share extra tariff costs
  • CA orders law enforcers to complete all election preparations by December
    CA orders law enforcers to complete all election preparations by December

Related News

  • One dies from COVID-19 in 24 hrs
  • Covid-19: Two more deaths, 7 new cases reported in 24hrs
  • Covid-19: One more death, 10 new cases reported in 24hrs
  • Three die from Covid-19 in 24 hrs
  • Five Covid-19 deaths reported in 24 hours, 36 new cases detected

Features

Women are forced to fish in saline waters every day, risking their health to provide for their families. Photo: TBS

How Mongla’s women are bearing the brunt of rising salinity

18h | Panorama
Dr Mostafa Abid Khan. Sketch: TBS

Actual impact will depend on how US retailers respond: Mostafa Abid Khan

2d | Economy
Thousands gather to form Bangla Blockade in mass show of support. Photo: TBS

Rebranding rebellion: Why ‘Bangla Blockade’ struck a chord

2d | Panorama
The Mitsubishi Xpander is built with families in mind, ready to handle the daily carpool, grocery runs, weekend getaways, and everything in between. PHOTO: Akif Hamid

Now made-in-Bangladesh: 2025 Mitsubishi Xpander

3d | Wheels

More Videos from TBS

Trump has been nominated for the Nobel Peace Prize before

Trump has been nominated for the Nobel Peace Prize before

45m | TBS World
Trump threatens to impose 50 percent tariffs on Brazil

Trump threatens to impose 50 percent tariffs on Brazil

2h | TBS World
Can India stop water flow to Pakistan?

Can India stop water flow to Pakistan?

3h | TBS World
SSC exam results are out today, results will be available via SMS

SSC exam results are out today, results will be available via SMS

4h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net